Generics 51

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Tofacitinib manufacturers

51 products found

Filters

51 products found

tofacitinib

Tablets, extended release (ER) 11 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Manufacturer #21467

This global pharmaceutical company is dedicated to improving patients' lives through high-quality, differentiated products and services. They leverage a collaborative network to achieve success in key regions like the EU and North America. Their focus areas include women's health, infectious diseases, and potentially other therapeutic areas based on their recent approvals and launches. They produce prescription medications (including injectables) and tablets, demonstrating expertise in various dosage forms. The company holds GMP certifications and boasts successful product patents, solidifying its commitment to quality and innovation.

Manufacturer usually replies in 0 days

tofacitinib

Tablets, film coated 5 mg, 10 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
South Africa , Vietnam
Manufacturer #21467

This global pharmaceutical company is dedicated to improving patients' lives through high-quality, differentiated products and services. They leverage a collaborative network to achieve success in key regions like the EU and North America. Their focus areas include women's health, infectious diseases, and potentially other therapeutic areas based on their recent approvals and launches. They produce prescription medications (including injectables) and tablets, demonstrating expertise in various dosage forms. The company holds GMP certifications and boasts successful product patents, solidifying its commitment to quality and innovation.

Manufacturer usually replies in 0 days

tofacitinib

Tablets, extended release (ER) 11 mg, 22 mg

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Ref. Xeljanz
Manufacturer #31058

This company, based in Europe, is a pharmaceutical manufacturer with a history spanning over seven decades. They focus on the development, production, and marketing of generic and value-added medicines, catering to patients globally. Their expertise lies in complex generics and their portfolio includes prescription drugs and over-the-counter medications. They hold significant experience in the industry, with strong manufacturing capabilities in Europe and North America, backed by GMP certifications. The company has a robust track record of growth, demonstrated by its international presence and expansion into key regions such as Europe and North America. Key therapy areas include cardiovascular, oncology, and gastrointestinal disorders. Their production lines include solid dosage forms, injectables, and liquids.

Manufacturer usually replies in 2 days

Want to see all 51 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription
Markets of interest JAK (Janus kinase) inhibitor, tofacitinib used to treat moderate to severe rheumatoid arthritis, active psoriatic arthritis and moderate to severe ulcerative colitis. The substance is used alone or with other pharmaceutical products, including methotrexate or certain similar medications for rheumatoid arthritis patients. The medication is prescribed to people with ulcerative colitis who are unable to take or who did not respond to tumor necrosis factor (TNF) inhibitor medications. The drug blocks the body’s immune response by decreasing janus kinase enzymes’ activity, which may stop the inflammatory process in ulcerative colitis. The medication is available for sale in the form of tablets (at concentrations of 5mg, and 10 mg), film coated tablets (at concentration 5mg) or extended release (er) tablets (at concentration of 11 mg), and provided by a wide range of tofacitinib suppliers from various countries including the Y, Y, and Y. Mostly due to the availability of raw materials for the manufacturing process and low labor costs, the leading tofacitinib manufacturers and distributors are based in India and China. Licensing and brand names Tofacitinib was approved by the FDA for the treatment of severely active rheumatoid arthritis in the United States in 2012, in 2017 for the treatment of active psoriatic arthritis, and in 2018, for the treatment of moderately to severely active ulcerative colitis. European Medical Agency (EMA) approved tofacitinib in 2017 for the treatment of severely active rheumatoid arthritis, and in 2018 for the treatment of active psoriatic arthritis and severely active ulcerative colitis. The drug is available for sale as a generic medication. Tofacitinib is marketed in some countries under the trade names Xeljanz. The leading tofacitinib supplier and manufacturer is the Chinese company Beijing THTD Pharmaceutical Technology Co. Ltd. Other manufacturing companies from India, Italy, Argentina, Russia, Turkey and Canada, have also successfully adapted to the demands of the global marketplace and produce a variant of the drug with tofacitinib as an active ingredient. Target supply price The wholesale acquisition cost of the tofacitinib supply of 56 tablets of 5 mg in the EU is about 758 EUR. The retail price in the USA reaches $4,916 for a supply of 60 tablets of 5mg each. The medication wholesale prices and commercial terms can vary depending on the supplier. Information from manufacturers We provide a detailed list of the tofacitinib manufacturers and suppliers that you are looking for. You can also find the dossier status of the drug that you order, and the GMP approvals of the different variants of the medication. The product description of all tofacitinib suppliers contains essential information about the medication, including clinical data, stability zones, and a list of countries where tofacitinib is already registered in. Manufacturers also specify the commercial terms of their offers, such as the market for which the offer is intended, deal type, dossier licensing fee, supply price, payment terms as well as delivery terms. Licensing and brand names Tofacitinib was approved by the FDA for the treatment of severely active rheumatoid arthritis in the United States in 2012, in 2017 for the treatment of active psoriatic arthritis, and in 2018, for the treatment of moderately to severely active ulcerative colitis. European Medical Agency (EMA) approved tofacitinib in 2017 for the treatment of severely active rheumatoid arthritis, and in 2018 for the treatment of active psoriatic arthritis and severely active ulcerative colitis. The drug is available for sale as a generic medication. Tofacitinib is marketed in some countries under the trade names Xeljanz. The leading tofacitinib supplier and manufacturer is the Chinese company Beijing THTD Pharmaceutical Technology Co. Ltd. Other manufacturing companies from India, Italy, Argentina, Russia, Turkey and Canada, have also successfully adapted to the demands of the global marketplace and produce a variant of the drug with tofacitinib as an active ingredient. Target supply price The wholesale acquisition cost of the tofacitinib supply of 56 tablets of 5 mg in the EU is about 758 EUR. The retail price in the USA reaches $4,916 for a supply of 60 tablets of 5mg each. The medication wholesale prices and commercial terms can vary depending on the supplier. Information from manufacturers We provide a detailed list of the tofacitinib manufacturers and suppliers that you are looking for. You can also find the dossier status of the drug that you order, and the GMP approvals of the different variants of the medication. The product description of all tofacitinib suppliers contains essential information about the medication, including clinical data, stability zones, and a list of countries where tofacitinib is already registered in. Manufacturers also specify the commercial terms of their offers, such as the market for which the offer is intended, deal type, dossier licensing fee, supply price, payment terms as well as delivery terms.

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible